Clinical Trials on Recurrent Cervical Carcinoma in Argentina

Total 327 results

Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Completed

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy (METIV-HCC)

Hepatocellular Carcinoma

United States, France, Italy, Germany, Spain, Switzerland, Belgium, Portugal, Netherlands, Australia, Brazil, Canada, Austria, New Zealand, Sweden, Argentina
GlaxoSmithKline

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)

Neoplasms, Head and Neck

United States, Italy, Japan, Norway, Spain, Taiwan, Australia, United Kingdom, Belgium, Brazil, Germany, Greece, Romania, Sweden, Turkey, Canada, Korea, Republic of, China, France, Argentina, India, Poland, Israel, Portugal, Mexico, Czechia, Hunga...
Exelixis

Recruiting

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304)

Non-Clear Cell Renal Cell Carcinoma

United States, Spain, Korea, Republic of, Italy, Australia, France, Argentina, Brazil, Chile, Czechia, Finland, Germany, Malaysia, Netherlands, Poland, Thailand
GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)

Neoplasms, Head and Neck

United States, Argentina, Australia, Spain, Taiwan, Germany, Israel, Poland, Canada, Japan, Portugal, Ireland, Netherlands, China, Brazil, France, Korea, Republic of, Italy, Romania, Russian Federation, United Kingdom, Norway, Switz... and more
Celltrion
Nippon Kayaku Co., Ltd.

Completed

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

HER2-positive Carcinoma of Breast

Italy, South Africa, Mexico, Japan, Taiwan, Russian Federation, Philippines, Hungary, Romania, Spain, Bosnia and Herzegovina, India, Peru, Ukraine, Latvia, Argentina, Georgia, Belarus, Chile, France, Poland, Portugal
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
H. Lundbeck A/S

Completed

Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder

Chile, Argentina, Colombia, Costa Rica, Estonia, Finland, France, Hungary, Peru, Russian Federation, South Africa
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Esophageal Squamous Cell Carcinoma (ESCC) | Gastroesophageal Junction Carcinoma (GEJC) | Esophageal Adenocarcinoma (EAC)

China, Canada, United States, Argentina, Belgium, Brazil, Chile, Czechia, Denmark, Estonia, France, Germany, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Mexico, Peru, Philippines, Portugal, Romania, Russian Federation and more
Sesen Bio, Inc.

Terminated

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Carcinoma, Squamous Cell | Neoplasms, Squamous Cell | Mouth Neoplasms | Carcinoma, Squamous Cell of Head and Neck

Spain, Germany, Israel, Italy, Poland, United Kingdom, India, Argentina, France, Hungary, Serbia, Croatia, Ukraine, Brazil, Russian Federation, Mexico, Romania, Slovakia
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

United States, France, Canada, Spain, Italy, Belgium, Austria, Denmark, Germany, Australia, Israel, Russian Federation, Czechia, Norway, Poland, Romania, Japan, Argentina, Ireland, Greece, United Kingdom, Brazil, Sweden, Finland
Janssen Research & Development, LLC

Recruiting

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)

Carcinoma, Non-Small-Cell Lung

United States, Taiwan, Korea, Republic of, Malaysia, Turkey, France, Spain, China, Germany, Argentina
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)

Hepatocellular Carcinoma

Germany, Romania, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Hong Kong, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland and more
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
AstraZeneca

Enrolling by invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D)

Cancer

United States, France, Italy, Spain, United Kingdom, Canada, Poland, Thailand, Vietnam, Germany, Korea, Republic of, Brazil, Hungary, India, Japan, Russian Federation, China, Malaysia, Australia, Turkey, Ukraine, Bulgaria, Taiwan, Arg... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (RECORD-3)

Renal Cell Carcinoma

Canada, United Kingdom, Hong Kong, Netherlands, United States, Thailand, Korea, Republic of, Spain, Australia, Denmark, Mexico, Germany, Turkey, Italy, France, Brazil, Peru, Taiwan, Argentina
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
GlaxoSmithKline

Completed

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

Italy, Argentina, Korea, Republic of, Estonia, Hong Kong, Ukraine, Ireland, Latvia, Pakistan, China, Austria, Greece, New Zealand, Poland, Russian Federation, United Kingdom, Australia, India, Czech Republic, Mexico, Brazil, Chile, ... and more
AstraZeneca

Completed

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

Carcinoma, Non- Small Cell Lung

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Peru, Russian Federation, Hong Kong, Israel, Greece, Australia, Singapore, Turkey, India, A...
OSI Pharmaceuticals
Canadian Cancer Trials Group

Completed

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Carcinoma, Non-small-cell Lung

Canada, United States, Australia, Singapore, Israel, China, Argentina, Germany, Sweden, Brazil, Chile, Greece, Mexico, New Zealand, Romania, South Africa, Thailand
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

Esophageal Squamous Cell Carcinoma

United States, France, Spain, Australia, Korea, Republic of, Argentina, Belgium, China, Portugal, Taiwan, Japan, Germany, Poland, Thailand, United Kingdom, Switzerland, Turkey, Russian Federation, Morocco, Greece, Italy, New Zealand, South Africa and more
AstraZeneca

Completed

Iressa Versus Docetaxel (Taxotere)

Non-Small-Cell Lung Carcinoma

United States, Croatia, Sweden, Italy, Mexico, Spain, Turkey, Germany, Philippines, Malaysia, China, Estonia, Latvia, Hong Kong, Argentina, Belgium, Canada, Denmark, France, Indonesia, Thailand, Brazil, Switzerland, Singapore, Slovenia
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Metastatic Esophageal Squamous Cell Carcinoma

Argentina, Chile, United States, Canada, China, Costa Rica, Denmark, France, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Romania, Ukraine, Singapore, Ma... and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, Brazil, Korea, Republic of, Spain, Argentina, United States, Costa Rica, Chile, Latvia, Finland, Italy, Poland
Sanofi

Completed

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Colorectal Neoplasms | Colorectal Carcinoma | Metastases

United States, Canada, Brazil, Poland, Australia, Germany, Italy, Portugal, Spain, Argentina, Hungary, United Kingdom, Chile
Telik

Completed

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States, Australia, Brazil, Chile, Germany, Argentina, Italy, United Kingdom
Pfizer

Completed

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib (INTORSECT)

Renal Cell Carcinoma

United States, Australia, Canada, Spain, France, Italy, Korea, Republic of, Denmark, Germany, United Kingdom, Singapore, Netherlands, Austria, Sweden, Chile, Argentina, China, Finland, Hungary, Switzerland
Pfizer

Active, not recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

United States, China, Japan, Mexico, Bulgaria, Argentina
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States, Israel, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Spain, Sweden, Ta... and more
Novartis Pharmaceuticals

Completed

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Canada, France, Italy, Spain, Belgium, Germany, Hungary, Saudi Arabia, Netherlands, Switzerland, Australia, Austria, Poland, Sweden, United Kingdom, Thailand, Korea, Republic of, Greece, Israel, Argentina, Japan, Colo... and more
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)

Hepatocellular Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Georgia, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Philippines, ... and more
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma (PRINCIPAL)

Carcinoma, Renal Cell

United States, Belgium, Estonia, Italy, Turkey, Austria, Argentina, Germany, Greece, Israel, Spain, United Kingdom, Taiwan, Hungary, Pakistan, Colombia, Finland, Lebanon
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)

Non-Small Cell Lung Cancer

Korea, Republic of, Canada, United States, Australia, Brazil, China, United Kingdom, Israel, Belgium, Netherlands, Argentina, Spain, Taiwan, Italy, Poland, Turkey, Sweden, Switzerland
Hoffmann-La Roche

Active, not recruiting

A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal)

Small Cell Lung Cancer | Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Urothelial Carcinoma

Hungary, United Kingdom, Belgium, Croatia, France, Italy, Spain, United Arab Emirates, Argentina, Bulgaria, Poland, Philippines, Serbia, Netherlands, Romania, Colombia, Austria, Russian Federation, Singapore, Estonia, Egypt, India, ... and more
GlaxoSmithKline

Completed

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Carcinoma, Renal Cell

Argentina, Korea, Republic of, Ukraine, Latvia, Pakistan, China, Austria, New Zealand, Poland, Russian Federation, United Kingdom, Australia, Brazil, Czech Republic, Chile, Italy, Lithuania, Slovakia, Tunisia, Estonia
Recombio SL
Eurofarma Laboratorios S.A.; Laboratorio Elea Phoenix S.A.; Innogene Kalbiotech... and other collaborators

Unknown

Immunotherapy With Racotumomab in Advanced Lung Cancer

NSCLC | Lung Cancer, Non-small Cell

Brazil, Indonesia, Argentina, Cuba, Philippines, Singapore, Thailand
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
Merck Sharp & Dohme LLC

Recruiting

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

Poland, United States, Argentina, Chile, Japan, Australia, France, New Zealand, South Africa, Turkey
AstraZeneca

Recruiting

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)

Papillary Renal Cell Carcinoma

China, Czechia, Israel, Netherlands, Spain, United Kingdom, Korea, Republic of, Italy, India, Mexico, Turkey, Argentina, Australia, Canada, Germany, Russian Federation, Taiwan, United States, Poland, Brazil, Chile, Hong Kong, Ukraine, Franc... and more
Novartis Pharmaceuticals

Completed

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)

Cancer | Renal Cell Carcinoma (RCC)

United States, Belgium, Canada, Spain, United Kingdom, Turkey, Austria, Argentina, Brazil, Czechia, France, Germany, Israel, Italy, Poland, Russian Federation, Korea, Republic of, Chile, China, Greece, Hungary, Ireland, Slovakia, Japan, Denmar... and more
Pfizer

Completed

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)

Renal Cell Carcinoma

France, Belgium, Hungary, Taiwan, United States, Australia, Spain, Hong Kong, Malaysia, Serbia, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation and more
Pfizer

Completed

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC)

Kidney Neoplasms | Carcinoma, Renal Cell

United States, Australia, Netherlands, Canada, Czech Republic, Poland, Russian Federation, Slovakia, Sweden, Turkey, Ukraine, Serbia, Italy, Spain, United Kingdom, Greece, Taiwan, Argentina, Mexico, Latvia, Hungary, Former Serbia... and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Renal Cell Carcinoma

France, Spain, Chile, United States, Argentina, Austria, Czechia, Greece, Italy, Mexico, Poland, Portugal, Romania, Russian Federation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966)

Biliary Tract Carcinoma

United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Spain, Taiwan, Thailand, Turkey, United Kingdom
AstraZeneca

Active, not recruiting

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) (CASPIAN)

Small Cell Lung Carcinoma Extensive Disease

Germany, United States, Poland, Taiwan, Turkey, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, China, Netherlands, Spain, Israel, Ukraine, Austria, France, Bulgaria, Romania, Argentina, Slovakia
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)

Renal Cell Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Singapore, Spain, Taiwan, United...
Boehringer Ingelheim

Completed

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Russian Federation, South Africa, Spain, Sweden, Switzerland
Heidelberg Pharma AG

Completed

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

Kidney Cancer

United States, Canada, Argentina, Brazil
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Hepatocellular Carcinoma

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, New Zealand, Norway, Poland, Russian Federation, Spai... and more

Clinical Trials on Recurrent Cervical Carcinoma in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations